: Investors: Bernie Hertel, Inovio Biomedical, 858-410-3101 Media: Jeff Richardson, Richardson & Associates, 805-491-8313 Ng Tee Khiang Appointed to Inovio Biomedical s Board o

SAN DIEGO, April 06,

2009 Inovio Biomedical Corporation (NYSE Amex: INO), a leader in enabling the

development of DNA vaccines using electroporation-based DNA delivery, announced today that Mr. Ng Tee Khiang has been appointed to the Company s Board of Directors.

years of entrepreneurial and investment management experience. He is a

co-founder, partner and director of multiple investment companies, including

Evia Capital Partners Pte. Ltd. and Evia Growth Opportunities Ltd. since 2004,

and has been a director of Grenidea Technologies Pte. Ltd. since 2003, of

Venture TDF Pte. Ltd. since 2001 and of Wing Huat Loong Pte. Ltd. since

1991. He has also been Chairman and

Director of CNT Health Food Pte. Ltd., a nutraceutical supplements contract

manufacturer, since 2000. In such

positions, Mr. Ng has focused on seed, pre-IPO, and IPO investment

opportunities. From 2002 through 2006, Mr. Ng served as a director of Asia

Growth Opportunities Ltd. and Raintree Ventures, investors in Inovio. In the 1990s, he was chairman of three

technology companies, Vital Technology, MediaRing Ltd., and AceFusion, helping secure

seed and venture capital, guide strategic growth, and facilitate sale of the

companies (Vital and Acefusion) or a public listing (MediaRing). Mr. Ng

has an M.Sc. in Industrial Engineering from Stanford University.

Ng Tee Khiang has worked extensively with

technology growth companies and we welcome him to Inovio s board of directors,

said Dr. Avtar Dhillon, Inovio s president, CEO and a director.

About Inovio Biomedical

Inovio Biomedical is focused

on developing DNA vaccines for cancers and infectious diseases using its novel

method for DNA delivery electroporation which uses brief, controlled

electrical pulses to increase cellular uptake of useful biopharmaceuticals.

Initial human data has shown that Inovio s electroporation-based DNA delivery

technology can significantly increase gene expression and immune responses from

DNA vaccines. Immunotherapy partners include Merck, Wyeth, Tripep, Vical,

University of Southampton, Moffitt Cancer Center, the U.S. Army, National

Cancer Institute, and International Aids Vaccine Initiative. Inovio s

technology is protected by an extensive patent portfolio covering in vivo electroporation. The company has entered into a

definitive merger agreement with VGX Pharmaceuticals. More information is

available at www.inovio.com.

and the public are encouraged to read the relevant pending registration and

proxy solicitation-related documents filed with the SEC with respect to the

pending transaction between Inovio and VGX Pharmaceuticals because they contain

important information about the companies, the transaction, the securities to

be issued and the expectations for the combined company. The pending

registration statement/proxy statement filed on Form S-4 and other

merger-related documents are available, without charge, from the SEC s web site

be obtained, free of charge, by requesting such documents, including any items

incorporated by reference, from Inovio.

press release contains certain forward-looking statements relating to our plans

to develop our electroporation drug and gene delivery technology and our

pending merger transaction. Actual events or results may differ from our

expectations as a result of a number of factors, including the uncertainties

inherent in clinical trials and product development programs, including, but

not limited to, the fact that pre-clinical and clinical results referenced in

this release may not be indicative of results achievable in other trials or for

other indications and that results from one study may not necessarily be

reflected or supported by the results of other similar studies. These factors

also include issues involving patents and whether they or licenses to them will

provide Inovio with meaningful protection from others using the covered

technologies, whether such proprietary rights are enforceable or defensible or

infringe or allegedly infringe on rights of others or can withstand claims of

invalidity and whether Inovio can finance or devote other significant resources

that may be necessary to prosecute, protect or defend them, assessments of our

technology by potential corporate or other partners or collaborators, issues

pertaining to Inovio s pending merger transaction including the timing and

outcome of the registration and stockholder approval processes required prior

to any closing of the transaction, if it closes at all, and other factors set

forth in our Annual Report on Form 10-K for the year ended December 31,

2008 and other regulatory filings from time to time. There can be no assurance

that any product in our product pipeline will be successfully developed or

manufactured, that final results of clinical studies will be supportive of

regulatory approvals required to market licensed products, or that any of the

forward-looking information provided herein will be proved accurate.